History of laparotomy by midline incision | 32/43 | (76.1%) |
 Colostomy | 4/32 | (12.5%) |
 More than two laparotomies | 3/32 | (9.4%) |
Preoperative chemotherapy (n = 14) | Â | Â |
 mFOLFOX6 + bevacizumab | 8 |  |
 mFOLFOX6 | 4 |  |
 FOLFOX4 + bevacizumab | 1 |  |
 FOLFIRI + bevacizumab | 1 |  |
 Median cycle number (course) | 7.2 ± 2.4 |  |
Indications for preoperative chemotherapy | Â | Â |
 Received chemotherapy in other institution | 7 |  |
 Presence of extrahepatic metastasis | 3 |  |
 Large and multiple tumors | 2 |  |
 Emergency surgery for primary tumor | 2 |  |
Surgical procedures | Â | Â |
 Pure laparoscopic liver resection | 26 | (60.5%) |
 HALS | 9 | (20.9%) |
 Laparoscopy-assisted liver resection | 8 | (18.6%) |
Recurrence in the remnant liver | 16/43 | (37.2%) |
Repeat hepatectomy | 6/16 | (37.5%) |
Repeat hepatectomy underwent LLH | 3/6 | (50.0%) |